

Indoco Remedies Q2 Net Revenues rise 9% Y-o-Y to ₹ 248 crore

Mumbai, October 30, 2015:

Indoco Remedies posted net revenues of ₹ 247.7 crores for the second quarter of July-Sept, up by 9.4 %, as against ₹ 226.4 crores for the same period last year. Profit After Tax (PAT) for the quarter was at ₹ 22.6 crores compared to ₹ 22.4 crores in the corresponding quarter last year.

Commenting on the quarterly performance, Aditi Panandikar, Managing Director, Indoco Remedies said, *“Company’s re-structuring process of domestic marketing divisions including field force expansion, taken up in the beginning of the year is expected to yield good results in the future. Performance of new products and prescription trend as per market data (CMARC & AWACs) have already started indicating positive trend. The international business has also done well by recording a growth of 24% during the second quarter”.*

The Company’s domestic formulation business introduced six new products during the quarter. Two of the new products are in Pain / Analgesics, two in Stomatological and one each in Gynaec & Anti-Diabetic segment. For the US markets, the Company has 61 ANDAs at various stages, including 9 approvals, 19 pending for approvals and 33 under development.

For the quarter ended Sept’15, the financials are as under:

(₹ in Crores)				
Particulars	July-Sept’15	% to Sales	July-Sept’14	% to Sales
Net Revenue	247.7		226.4	
EBIDTA	45.7	18.5	48.6	21.5
Profit Before Tax	28.5	11.5	33.4	14.7
Profit After Tax	22.6	9.1	22.4	9.9
EPS (Face value ₹ 2/-)	2.45		2.43	

About Indoco Remedies Limited:

Indoco Remedies Ltd., headquartered in Mumbai, is a fully integrated, research-oriented pharma Company with presence in 55 countries. Indoco, a USD 136 million Company, employs over 5500 people including 300 skilled scientists.

The Company has 8 manufacturing facilities, 5 of which are for FDFs and 3 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by USFDA, UK-MHRA, TGA-Australia, MCC-South Africa, etc. Indoco develops and

manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 60 million prescriptions annually from around 2,00,000 doctors in India. Indoco has 10 domestic marketing divisions with a strong brand portfolio in various therapeutic segments including Respiratory, Anti-Infective, Dental Care, Pain Management, Gastro-intestinal, Ophthalmic, Cardiovascular, Anti-Diabetics, Anti-Obesity, etc. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, ATM, Oxipod, Cital, Sensoform, Cloben-G, Sensodent-KF, Karvol Plus, Glychek, Vepan, Tuspel Plus, Flamar, etc. On the international front, Indoco has tie-ups with large generic companies like Watson (Actavis) – USA and ASPEN-South Africa.

For more details on Indoco, you may visit www.indoco.com

For Media Inquiries Please Contact:

Kailash Rajwadkar

Mobile: 9869333999 / 9869111687

E-mail: kailash.rajwadkar@gmail.com

Vilas V. Nagare

Mobile: 9820215745

E-mail: vilasn@indoco.com